Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

VYNE Therapeutics Q2 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $198.000K Beat $110.000K Estimate

Author: Benzinga Newsdesk | August 14, 2024 08:07am
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.19) by 15.79 percent. The company reported quarterly sales of $198.000 thousand which beat the analyst consensus estimate of $110.000 thousand by 80.00 percent. This is a 46.67 percent increase over sales of $135.000 thousand the same period last year.

Posted In: VYNE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist